How will the CPP issue affect MSFs effort to get new LPV/r to its projects?
Because MSF will be trying to obtain special authorization to get new LPV/r to its projects, the CPP question is not relevant right now, as it is a requirement related to registration in some countries. But it is important to understand that Abbott’s excuse for its delay in registering this urgently needed formulation in Africa is not based on the WHO or country requirements. If Abbott wanted to facilitate the long-term availability of the new formulation of LPV/r as soon as possible, it could file for registration in those countries that do not require a CPP now and request a CPP from the US in order to file in all remaining countries.
Related Questions
- How does that-- you explained how the rule which affects the scientific conclusions, how does it affect the religious issue?
- How does that-- you explained how the rule which affects the scientific conclusions, how does it affect the religious issue?
- Will the progressive fee affect costs in third world nations. Isn’t there a justice issue?
- How will the CPP issue affect MSFs effort to get new LPV/r to its projects?
- How will Iran issue affect the Afghanistan process?
- How will Iran issue affect the Afghanistan process?
